Completed PHASE1 INTERVENTIONAL 1-arm NCT04309643

Drug-drug Interaction Study of CTP-543 and Oral Contraceptives in Healthy Female Subjects

A Phase 1, Open-label Study to Assess the Effect of CTP-543 on the Pharmacokinetics of Oral Contraceptives in Healthy Adult Female Subjects

Sponsor: Celerion

Conditions Healthy Volunteers

Interventions CTP-543 Combined oral contraceptive containing Ethinyl estradiol (EE) and Levonorgestrel (LNG)

Updated 6 times since 2020 Last updated: Jul 14, 2020 Started: Jun 9, 2020 Primary completion: Jun 25, 2020 Completion: Jul 8, 2020

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT04309643, this PHASE1 trial focuses on Healthy Volunteers and remains completed. Sponsored by Celerion, it has been updated 6 times since 2020, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Aug 2020 — Jan 2021 [monthly]

Completed PHASE1

Status: Active Not Recruiting → Completed
Jul 2020 — Aug 2020 [monthly]

Active Not Recruiting PHASE1

Status: Not Yet Recruiting → Active Not Recruiting

▶ Show 1 earlier version

Apr 2020 — Jul 2020 [monthly]

Not Yet Recruiting PHASE1

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Celerion
Concert Pharmaceuticals

Data source: Concert Pharmaceuticals

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Tempe, United States